To evaluate docetaxel in combination with cisplatin weekly regimen induced synchronous radiotherapy and chemotherapy in III. I N: stage non-small cell lung cancer treatment in terms of efficacy and safety. Methods Retrospective analysis of 18 cases from March 2011 to November 2013 of III. I N: stage non-small cell lung cancer patients with a treatment plan of preoperative induction radiotherapy + surgery. The induction chemotherapy was DP weekly regimen (docetaxel 20 mg/m2 + cisplatin 20 mg/in2) for 5 cycles with a total dose of 45 Gy of simultaneous radiotherapy; patients with non-disease progression after induction therapy received surgery; postoperative adjuvant chemotherapy was then given with DP regimen. As a result, 16 cases completed induction therapy. There were 5 cases of grade III or higher adverse reactions to induction therapy, including 2 cases of neutropenia and 1 case each of liver damage, lymph node infection and anemia. After induction therapy, there was one case of complete remission on imaging, 10 cases of partial remission, 6 cases of stable disease, and one case of disease progression. 12 patients finally underwent surgery with a median operative time of 290 min, bleeding volume of 350 ml, time with tube for 5 days, and 7 days of postoperative hospitalization. The mediastinal lymph node step-down rate was 50% (3 pN0, 3 pN,) and complete resection was achieved in 92% of patients. 1-year survival rate was 75.9% and 1-year progression-free survival rate was 49.2%. Conclusion Induction-based synchronous radiotherapy combined with surgery based on a weekly regimen of docetaxel + cisplatin is effective for III. I N2 stage non-small cell lung cancer patients with definite efficacy and good safety.